Objective: Polycystic ovary syndrome (PCOS) is one the most common metabolic and endocrine disorders in women, which is always accompanied with obesity and insulin resistance (IR). Glucagon-like peptide-1 (GLP-1) has been investigated to decrease body weight and IR in PCOS, and it appears superior combined with metformin (MET) than MET alone. Benaglutide is the first human homologous GLP-1 drug. It had been shown in previous studies to reduce blood glucose and have effect on weight loss. The potential impact of preconception intervention with benaglutide on improving IR and weight loss in PCOS has not been evaluated yet.
Methods: This is a 12-week open-label randomized clinical study.88 overweight/obese (OW/OB) patients with PCOS, who had already received MET 1000 mg Bid treatment for more than 3 months. They were randomized into two groups, to receive either benaglutide (BEN) 0.2 mg ih tid and MET 1000 mg bid (N=35, age: 27.6±5.7, BMI: 28.33±3.36 kg/m2, mean±s.d.) or exenatide (EXE) 10ug ih bid and MET 1000 mg bid (N=33, age: 27.7±6.5, BMI: 28.82±3.44 kg/m2) per day. We observed BMI, OGTT 0- and 2-hour blood glucose, HOMAIR, blood lipids and sexual hormones, at 0 and 12 weeks. Lifestyle intervention was promoted in both groups.
Results: BMI had decreased in the BEN group 1.89±1.55 kg/m2 (p<0.05) compared with 1.83±1.17 kg/m2 (p<0.05) in the EXE group. OGTT 2-hour blood glucose was reduced 0.97±1.80 mmol/l (p<0.05) in the BEN group with 1.43±2.86 mmol/l (p<0.05) in the EXE group. In the BEN group, HOMAIR decreased 1.38±2.86 (p<0.05) as well as in the EXE group 1.61±2.08 (p<0.05), whereas measures of OGTT 0h blood glucose, blood lipids and sex hormones did not change. From all the indexes no significant between-treatment difference (p>0.05) were found in the two groups.
Conclusions: Benaglutide combined with metformin treatment in overweight/obese women with PCOS appears superior decrease in BMI, OGTT 2-hour blood glucose and HOMAIR, the efficiencies were same as exenatide with metformin.
J. Chen: None. Q. Sun: None. M. Zhang: None. H. Tian: None. S. Chen: None.